Haematology 2018

Phase II study Response rates

High response rates in relapsed/refractory MCL 1

ibrutinib ® delivered high response rates in relapsed/refractory MCL. 1 • Responses were often seen early (median 1.9 months to initial response) and generally continued to improve over time 1

Graph adapted from WangM, etal. 2013.

Partial response: Regression of measurable disease and no new sites. 2 Complete response: Disappearance of all evidence of disease. 2 (Revised International Working Group Criteria for non-Hodgkin’s lymphoma)

MCL: mantle cell lymphoma. 1. Wang M et al. N Engl J Med 2013; 369: 507-516.